This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prystowsky, J.
Right arrow Articles by Noskin, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prystowsky, J.
Right arrow Articles by Noskin, G. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2001, p. 2154-2156, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2154-2156.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Resistance to Linezolid: Characterization of Mutations in rRNA and Comparison of Their Occurrences in Vancomycin-Resistant Enterococci

Jason Prystowsky,1 Farida Siddiqui,1 John Chosay,2 Dean L. Shinabarger,2 John Millichap,3 Lance R. Peterson,3,4 and Gary A. Noskin1,4,*

Department of Medicine, Division of Infectious Diseases,1 and Department of Pathology, Clinical Microbiology Division,3 Northwestern University Medical School, and the Prevention Epicenter, Northwestern Memorial Hospital,4 Chicago, Illinois, and Pharmacia Corporation, Kalamazoo, Michigan2

Received 11 December 2000/Returned for modification 29 January 2001/Accepted 28 March 2001


    ABSTRACT
Top
Abstract
Text
References

To assess the potential for emergence of resistance during the use of linezolid, we tested 10 clinical isolates of vancomycin-resistant enterococci (VRE) (four Enterococcus faecalis, five Enterococcus faecium, and one Enterococcus gallinarum) as well as a vancomycin-susceptible control (ATCC 29212) strain of E. faecalis. The enterococci were exposed to doubling dilutions of linezolid for 12 passes. After the final passage, the linezolid plate growing VRE contained a higher drug concentration with E. faecalis than with E. faecium. DNA sequencing of the 23S rRNA genes revealed that linezolid resistance in three E. faecalis isolates was associated with a guanine to uracil transversion at bp 2576, while the one E. faecium isolate for which the MIC was 16 µg/ml contained a guanine to adenine transition at bp 2505.


    TEXT
Top
Abstract
Text
References

Vancomycin-resistant enterococci (VRE) have emerged as important nosocomial pathogens in medical centers throughout the United States. Over the last decade, the incidence of VRE has been increasing, and currently nearly one-quarter of enterococci isolated from patients in intensive care units are vancomycin resistant (2, 9). In addition, these organisms are capable of prolonged survival on the hands of healthcare workers as well as on environmental surfaces commonly encountered in the healthcare setting (11).

Linezolid is a member of a new class of antibacterial agents called the oxazolidinones, which are chemically unrelated to currently available agents. This agent selectively binds to the 50S ribosomal subunit, thereby resulting in inhibition of bacterial protein synthesis (6). These compounds are unique in that they do not inhibit elongation (3, 4, 14) but instead inhibit the formation of the initiation complex constructed with 70S ribosomes, mRNA, initiation factors IF2 and IF3, and formylmethionyl-tRNA (15). Linezolid is highly active against gram-positive organisms, including VRE (10). The purposes of this study were to select for VRE resistant to linezolid in vitro and to investigate the stability of this resistance, if it could be developed.

We chose 10 clinical isolates of VRE, 5 of which were Enterococcus faecium (EF208, EF1347, EF1401, EF1509, and EF1644), 4 of which were Enterococcus faecalis (F118, F177, F217, and F317), and 1 of which was Enterococcus gallinarum (Z393). All were isolated from patients at Northwestern Memorial Hospital, Chicago, Ill. Vancomycin resistance (screened for by using a MIC of >= 6 µg/ml as recommended by the NCCLS) was determined by agar dilution (Difco Laboratories, Detroit, Mich.) testing according to the National Committee for Clinical Laboratory Standards (8). E. faecalis ATCC 29212 was tested as a vancomycin-susceptible control. All isolates were initially tested for their baseline activity against linezolid (Pharmacia Corp., Kalamazoo, Mich.) according to a standard tube dilution method (8). Susceptibility testing was performed using doubling dilutions ranging from 0.25 to 8 µg/ml. The MIC was defined as the lowest concentration of the antibiotic that exhibited no visible turbidity. The susceptibility breakpoint for linezolid is <= 4 µg/ml.

The basic approach used to select for resistance utilized serial passage on successively higher concentrations, similar to the methods previously applied to the selection of E. faecium highly resistant to quinupristin-dalfopristin (7). To examine the stability of resistance, the isolates were subcultured to drug-free agar twice weekly for one month and then tested by the agar dilution method (8) to determine the final linezolid MIC.

Cultures were grown overnight in 50 ml of brain heart infusion broth at 37°C. Chromosomal DNA was isolated as described by Baele and colleagues (1), except that the cell lysate was extracted twice with phenol-chloroform-isoamyl alcohol (24:25:1) before the DNA was precipitated with ethanol. PCR was then carried out using the primers 5'-GACGGAAAGACCCCATGG-3' and 5'-ACACTTAGATGCTTT-3' corresponding to bp 2049 to 2767. Amplification was carried out using Taq DNA polymerase (Gibco) according to the manufacturer's directions.

PCR products were sequenced directly by using an ABI377 fluorescence sequencer (Perkin-Elmer Applied Biosystems, Foster City, Calif.) and the ABI BigDye Terminator Cycle Sequencing Ready Reaction kit with AmpliTaq FS DNA polymerase (Perkin-Elmer Applied Biosystems).

A summary of the results of this investigation is provided in Table 1. The initial linezolid MIC, tested by broth dilution, for all VRE and the ATCC 29212 strain was 1 µg/ml. Selection of linezolid-resistant mutants occurred for all four of the vancomycin-resistant E. faecalis strains and the vancomycin-susceptible control strain. The final MIC for one of the vancomycin-resistant E. faecium strains was 16 µg/ml, while the final MICs for the remaining E. faecium isolates and the E. gallinarum isolate were <= 8 µg/ml, despite multiple attempts to select for resistant mutants. Two of these isolates (EF 1401 and EF 1509) were from patients who were previously treated with linezolid for VRE bacteremia. In neither of these strains were we able to select for resistance despite prior clinical exposure to this antimicrobial agent.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Results of in vitro selection of linezolid-resistant enterococci

Interestingly, the vancomycin-resistant E. faecalis strains developed resistance to linezolid more rapidly and to a greater extent than did E. faecium strains. For E. faecalis, the range for the final-pass MICs was 32 to 128 µg/ml; however, for E. faecium, the range was 2 to 16 µg/ml. Selection of linezolid-resistant mutants occurred for all strains of E. faecalis tested, but at various rates; the MICs developed for three of the four strains by passage 5 were >= 16 µg/ml.

For only one isolate (F317) was there a change in the final linezolid MIC following growth on drug-free media for one month, and this represented a twofold change from the final-pass MIC after one month of growth on drug-free media.

Resistance to linezolid is uncommon based on in vitro results as well as those from clinical trials. A relatively low spontaneous mutation frequency has been observed with linezolid and is consistent with the results obtained with other oxazolidinones (4, 12). Previous investigations with staphylococci failed to identify spontaneous mutants at twice the MIC and higher, resulting in a calculated spontaneous mutational frequency of less than 10-9 to 10-11 (5, 16). In addition, serial passage of both enterococci and staphylococci on gradient plates has failed to produce a high frequency of resistant mutants (16).

Our results suggest that it is more difficult to select for enterococci resistant to linezolid than to quinupristin-dalfopristin (7). For E. faecalis, we were able to select for resistance in all four of the isolates, which began to develop after three passes. In contrast, for vancomycin-resistant E. faecium, resistance did not begin to develop until at least 10 passes. When similar selection studies were performed with quinupristin-dalfopristin, high-level resistance developed very rapidly with all isolates tested (7). The data also suggest that when significant resistance (above the MIC breakpoint, 4 µg/ml) develops, it is stable, as it was with experiments performed with quinupristin-dalfopristin.

PCR amplification of the 23S rRNA gene region corresponding to the peptidyl transferase site revealed that the linezolid-resistant E. faecalis isolates F118, F217, F317, and ATCC 29212 all had a guanine to uracil conversion at bp 2576 (Fig. 1). This G2576U mutation had been previously described for two E. faecium isolates obtained from two separate patients who developed resistance to linezolid while on therapy (G. E. Zurenko, W. M. Todd, B. Hafkin, B. Meyers, C. Kauffman, A. Bock, J. Slightom, and D. Shinabarger, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-848, 1999). Both of these patients received prolonged courses of linezolid for VRE bacteremia with infected intravascular devices that could not be removed. In addition, G2576U has occurred in both E. faecalis and S. aureus selected for resistance to the oxazolidinone eperezolid in the laboratory (13; S. M. Swaney, D. L. Shinabarger, R. D. Schaadt, J. H. Bock, J. L. Slightom, and G. E. Zurenko, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-104, 1998). E. faecalis F217 was particularly unusual in that it contained three mutations (C2512U, G2513U, and C2610G) in addition to G2576U. The contribution of these three unusual mutations to the level of linezolid resistance is unknown since the MIC for F217 and ATCC 29212 was the same.


View larger version (21K):
[in this window]
[in a new window]
  		FIG. 1.   Location of linezolid-resistant mutations in the enterococcal 23S rRNA peptidyl transferase region.

In order to determine whether linezolid-resistant E. faecium isolates contained 23S rRNA mutations, EF1644 was sequenced because it exhibited the highest level of resistance (16 µg/ml) compared to the other four E. faecium isolates from this study. Interestingly, EF1644 was found to contain a new mutation at G2505A not previously found in oxazolidinone-resistant bacteria. DNA sequencing of E. gallinarum Z393 (MIC for the strain, 8 µg/ml) failed to detect any mutations in the peptidyl transferase region. We are continuing to sequence the genes which encode 23S and 16S rRNAs, as well as the genes which encode ribosomal proteins, in Z393 in order to determine whether a mutation is indeed present.

Overall, our investigation demonstrates the potential for development of resistance to linezolid among vancomycin-resistant E. faecalis strains; however, there was difficulty in selecting for resistance in vancomycin-resistant E. faecium isolates. In addition, these results suggest that the mechanism of resistance for E. faecalis and E. faecium may be different. Our data suggest that linezolid has a finite but low propensity for the selection of resistance in vancomycin-resistant E. faecium strains.


    ACKNOWLEDGMENTS

This work was supported in part by the Medical School Research Grant Program, Northwestern University Medical School, and Pharmacia.

We thank C. Bannigan and J. Slightom for DNA sequencing.


    FOOTNOTES

* Corresponding author. Mailing address: Division of Infectious Diseases, Northwestern University Medical School, Feinberg 16-704, 251 E. Huron St., Chicago, IL 60611. Phone: (312) 926-2729. Fax: (312) 926-7845. E-mail: gnoskin{at}northwestern.edu.


    REFERENCES
Top
Abstract
Text
References

1. Baele, M., P. Baele, M. Vaneechoutte, V. Storms, P. Butaye, L. A. Devriese, G. Verschraegen, M. Gillis, and F. Haesebrouck. 2000. Application of tRNA intergenic spacer PCR for identification of enterococcus species. J. Clin. Microbiol. 38:4201-4207[Abstract/Free Full Text].
2. Centers for Disease Control and Prevention. 1999. National Nosocomial Infection Surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532[CrossRef][Medline].
3. Daly, J. S., G. M. Eliopoulos, E. Reiszner, and R. C. Moellering, Jr. 1988. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J. Antimicrob. Chemother. 21:721-730[Abstract/Free Full Text].
4. Daly, J. S., G. M. Eliopoulos, S. Willey, and R. C. Moellering, Jr. 1988. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob. Agents Chemother. 32:1341-1346[Abstract/Free Full Text].
5. Kaatz, G. W., and S. M. Seo. 1996. In vitro activities of oxazolidinone compounds U-100592 and U-100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 40:799-801[Abstract].
6. Lin, A. H., R. W. Murray, T. J. Vidmar, and K. R. Marotti. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob. Agents Chemother. 41:2127-2131.
7. Millichap, J., T. A. Ristow, G. A. Noskin, and L. R. Peterson. 1996. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using step-wise in vitro exposure. Diagn. Microbiol. Infect. Dis. 25:15-20[CrossRef][Medline].
8. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Noskin, G. A. 1997. Vancomycin-resistant enterococci: clinical, microbiologic, and epidemiologic features. J. Lab. Clin. Med. 130:14-20[CrossRef][Medline].
10. Noskin, G. A., F. Siddiqui, V. Stosor, D. Hacek, and L. R. Peterson. 1999. In vitro activity of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 43:2059-2062[Abstract/Free Full Text].
11. Noskin, G. A., V. Stosor, I. Cooper, and L. R. Peterson. 1995. Recovery of vancomycin resistant enterococci on fingertips and environmental surfaces. Infect. Control Hosp. Epidemiol. 16:577-581[Medline].
12. Schaadt, R. D., D. H. Batts, P. T. Daley-Yates, S. D. Pawsey, D. J. Stalker, and G. E. Zurenko. 1997. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diagn. Microbiol. Infect. Dis. 28:201-204[CrossRef][Medline].
13. Shinabarger, D. 1999. Mechanism of action of the oxazolidinone antibacterial agents. Exp. Opin. Investig. Drugs 8:1195-1202.
14. Shinabarger, D. L., K. R. Marotti, R. W. Murray, A. H. Lin, E. P. Melchior, S. M. Swaney, D. S. Dunyak, W. F. Demyan, and J. M. Buysse. 1997. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41:2132-2136[Abstract].
15. Swaney, S. M., H. Aoki, M. C. Ganoza, and D. L. Shinabarger. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42:3251-3255[Abstract/Free Full Text].
16. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845[Abstract].

Antimicrobial Agents and Chemotherapy, July 2001, p. 2154-2156, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2154-2156.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Boumghar-Bourtchai, L., Dhalluin, A., Malbruny, B., Galopin, S., Leclercq, R. (2009). Influence of Recombination on Development of Mutational Resistance to Linezolid in Enterococcus faecalis JH2-2. Antimicrob. Agents Chemother. 53: 4007-4009 [Abstract] [Full Text]  
  • Cian, F., Luzzati, R., Deiana, M. L., Ferrantelli, N., Tonin, E., Lagatolla, C., Dolzani, L. (2009). Colonization of the tip of a thoracic catheter by Enterococcus faecalis resistant to vancomycin and linezolid. J Med Microbiol 58: 1118-1121 [Abstract] [Full Text]  
  • Feng, J., Lupien, A., Gingras, H., Wasserscheid, J., Dewar, K., Legare, D., Ouellette, M. (2009). Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 19: 1214-1223 [Abstract] [Full Text]  
  • Davidovich, C., Bashan, A., Yonath, A. (2008). Structural basis for cross-resistance to ribosomal PTC antibiotics. Proc. Natl. Acad. Sci. USA 105: 20665-20670 [Abstract] [Full Text]  
  • Shaw, K. J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C. M., Shinabarger, D., Zurenko, G. (2008). In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains. Antimicrob. Agents Chemother. 52: 4442-4447 [Abstract] [Full Text]  
  • Skripkin, E., McConnell, T. S., DeVito, J., Lawrence, L., Ippolito, J. A., Duffy, E. M., Sutcliffe, J., Franceschi, F. (2008). R{chi}-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance. Antimicrob. Agents Chemother. 52: 3550-3557 [Abstract] [Full Text]  
  • Wilson, D. N., Schluenzen, F., Harms, J. M., Starosta, A. L., Connell, S. R., Fucini, P. (2008). The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc. Natl. Acad. Sci. USA 105: 13339-13344 [Abstract] [Full Text]  
  • Scheetz, M. H., Knechtel, S. A., Malczynski, M., Postelnick, M. J., Qi, C. (2008). Increasing Incidence of Linezolid-Intermediate or -Resistant, Vancomycin-Resistant Enterococcus faecium Strains Parallels Increasing Linezolid Consumption. Antimicrob. Agents Chemother. 52: 2256-2259 [Abstract] [Full Text]  
  • Lawrence, L., Danese, P., DeVito, J., Franceschi, F., Sutcliffe, J. (2008). In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens. Antimicrob. Agents Chemother. 52: 1653-1662 [Abstract] [Full Text]  
  • Kelly, S., Collins, J., Maguire, M., Gowing, C., Flanagan, M., Donnelly, M., Murphy, P. G. (2008). An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J Antimicrob Chemother 61: 901-907 [Abstract] [Full Text]  
  • Arias, C. A., Vallejo, M., Reyes, J., Panesso, D., Moreno, J., Castaneda, E., Villegas, M. V., Murray, B. E., Quinn, J. P. (2008). Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase. J. Clin. Microbiol. 46: 892-896 [Abstract] [Full Text]  
  • Hillemann, D., Rusch-Gerdes, S., Richter, E. (2008). In Vitro-Selected Linezolid-Resistant Mycobacterium tuberculosis Mutants. Antimicrob. Agents Chemother. 52: 800-801 [Full Text]  
  • Top, J., Willems, R., van der Velden, S., Asbroek, M., Bonten, M. (2008). Emergence of Clonal Complex 17 Enterococcus faecium in The Netherlands. J. Clin. Microbiol. 46: 214-219 [Abstract] [Full Text]  
  • Werner, G., Bartel, M., Wellinghausen, N., Essig, A., Klare, I., Witte, W., Poppert, S. (2007). Detection of Mutations Conferring Resistance to Linezolid in Enterococcus spp. by Fluorescence In Situ Hybridization. J. Clin. Microbiol. 45: 3421-3423 [Abstract] [Full Text]  
  • Hong, T., Li, X., Wang, J., Sloan, C., Cicogna, C. (2007). Sequential Linezolid-Resistant Staphylococcus epidermidis Isolates with G2576T Mutation. J. Clin. Microbiol. 45: 3277-3280 [Abstract] [Full Text]  
  • Tenover, F. C., Williams, P. P., Stocker, S., Thompson, A., Clark, L. A., Limbago, B., Carey, R. B., Poppe, S. M., Shinabarger, D., McGowan, J. E. Jr. (2007). Accuracy of Six Antimicrobial Susceptibility Methods for Testing Linezolid against Staphylococci and Enterococci. J. Clin. Microbiol. 45: 2917-2922 [Abstract] [Full Text]  
  • Jones, R. N., Stilwell, M. G., Hogan, P. A., Sheehan, D. J. (2007). Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 51: 1491-1493 [Abstract] [Full Text]  
  • Butler, M. M., LaMarr, W. A., Foster, K. A., Barnes, M. H., Skow, D. J., Lyden, P. T., Kustigian, L. M., Zhi, C., Brown, N. C., Wright, G. E., Bowlin, T. L. (2007). Antibacterial Activity and Mechanism of Action of a Novel Anilinouracil-Fluoroquinolone Hybrid Compound. Antimicrob. Agents Chemother. 51: 119-127 [Abstract] [Full Text]  
  • Seedat, J., Zick, G., Klare, I., Konstabel, C., Weiler, N., Sahly, H. (2006). Rapid Emergence of Resistance to Linezolid during Linezolid Therapy of an Enterococcus faecium Infection. Antimicrob. Agents Chemother. 50: 4217-4219 [Abstract] [Full Text]  
  • Marra, A. R., Major, Y., Edmond, M. B. (2006). Central Venous Catheter Colonization by Linezolid-Resistant, Vancomycin-Susceptible Enterococcus faecalis.. J. Clin. Microbiol. 44: 1915-1916 [Abstract] [Full Text]  
  • Qi, C., Zheng, X., Obias, A., Scheetz, M. H., Malczynski, M., Warren, J. R. (2006). Comparison of Testing Methods for Detection of Decreased Linezolid Susceptibility Due to G2576T Mutation of the 23S rRNA Gene in Enterococcus faecium and Enterococcus faecalis.. J. Clin. Microbiol. 44: 1098-1100 [Abstract] [Full Text]  
  • Bonora, M. G., Solbiati, M., Stepan, E., Zorzi, A., Luzzani, A., Catania, M. R., Fontana, R. (2006). Emergence of Linezolid Resistance in the Vancomycin-Resistant Enterococcus faecium Multilocus Sequence Typing C1 Epidemic Lineage.. J. Clin. Microbiol. 44: 1153-1155 [Abstract] [Full Text]  
  • Jones, R. N., Ross, J. E., Fritsche, T. R., Sader, H. S. (2006). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57: 279-287 [Abstract] [Full Text]  
  • Draghi, D. C., Sheehan, D. J., Hogan, P., Sahm, D. F. (2005). In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program. Antimicrob. Agents Chemother. 49: 5024-5032 [Abstract] [Full Text]  
  • Carsenti-Dellamonica, H., Galimand, M., Vandenbos, F., Pradier, C., Roger, P. M., Dunais, B., Sabah, M., Mancini, G., Dellamonica, P. (2005). In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides. J Antimicrob Chemother 56: 633-642 [Abstract] [Full Text]  
  • Swoboda, S., Fritz, S., Martignoni, M. E., Feldhues, R. A., Hoppe-Tichy, T., Buchler, M. W., Geiss, H. K. (2005). Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 56: 787-789 [Abstract] [Full Text]  
  • Wolter, N., Smith, A. M., Farrell, D. J., Schaffner, W., Moore, M., Whitney, C. G., Jorgensen, J. H., Klugman, K. P. (2005). Novel Mechanism of Resistance to Oxazolidinones, Macrolides, and Chloramphenicol in Ribosomal Protein L4 of the Pneumococcus. Antimicrob. Agents Chemother. 49: 3554-3557 [Abstract] [Full Text]  
  • Liao, C.-H., Tseng, S.-P., Fang, C.-T., Teng, L.-J., Hsueh, P.-R. (2005). First linezolid- and vancomycin-resistant Enterococcus faecium strain in Taiwan. J Antimicrob Chemother 55: 598-599 [Full Text]  
  • Treitman, A. N., Yarnold, P. R., Warren, J., Noskin, G. A. (2005). Emerging Incidence of Enterococcus faecium among Hospital Isolates (1993 to 2002). J. Clin. Microbiol. 43: 462-463 [Abstract] [Full Text]  
  • Werner, G., Strommenger, B., Klare, I., Witte, W. (2004). Molecular Detection of Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis by Use of 5' Nuclease Real-Time PCR Compared to a Modified Classical Approach. J. Clin. Microbiol. 42: 5327-5331 [Abstract] [Full Text]  
  • Raad, I. I., Hanna, H. A., Hachem, R. Y., Dvorak, T., Arbuckle, R. B., Chaiban, G., Rice, L. B. (2004). Clinical-Use-Associated Decrease in Susceptibility of Vancomycin-Resistant Enterococcus faecium to Linezolid: a Comparison with Quinupristin-Dalfopristin. Antimicrob. Agents Chemother. 48: 3583-3585 [Abstract] [Full Text]  
  • Dibo, I., Pillai, S. K., Gold, H. S., Baer, M. R., Wetzler, M., Slack, J. L., Hazamy, P. A., Ball, D., Hsiao, C. B., McCarthy, P. L. Jr., Segal, B. H. (2004). Linezolid-Resistant Enterococcus faecalis Isolated from a Cord Blood Transplant Recipient. J. Clin. Microbiol. 42: 1843-1845 [Abstract] [Full Text]  
  • Bersos, Z., Maniati, M., Kontos, F., Petinaki, E., Maniatis, A. N. (2004). First report of a linezolid-resistant vancomycin-resistant Enterococcus faecium strain in Greece. J Antimicrob Chemother 53: 685-686 [Full Text]  
  • Limburg, E., Gahlmann, R., Kroll, H.-P., Beyer, D. (2004). Ribosomal Alterations Contribute to Bacterial Resistance against the Dipeptide Antibiotic TAN 1057. Antimicrob. Agents Chemother. 48: 619-622 [Abstract] [Full Text]  
  • Sinclair, A., Arnold, C., Woodford, N. (2003). Rapid Detection and Estimation by Pyrosequencing of 23S rRNA Genes with a Single Nucleotide Polymorphism Conferring Linezolid Resistance in Enterococci. Antimicrob. Agents Chemother. 47: 3620-3622 [Abstract] [Full Text]  
  • Willems, R. J., Top, J., Smith, D. J., Roper, D. I., North, S. E., Woodford, N. (2003). Mutations in the DNA Mismatch Repair Proteins MutS and MutL of Oxazolidinone-Resistant or -Susceptible Enterococcus faecium. Antimicrob. Agents Chemother. 47: 3061-3066 [Abstract] [Full Text]  
  • Lobritz, M., Hutton-Thomas, R., Marshall, S., Rice, L. B. (2003). Recombination Proficiency Influences Frequency and Locus of Mutational Resistance to Linezolid in Enterococcus faecalis. Antimicrob. Agents Chemother. 47: 3318-3320 [Abstract] [Full Text]  
  • Colca, J. R., McDonald, W. G., Waldon, D. J., Thomasco, L. M., Gadwood, R. C., Lund, E. T., Cavey, G. S., Mathews, W. R., Adams, L. D., Cecil, E. T., Pearson, J. D., Bock, J. H., Mott, J. E., Shinabarger, D. L., Xiong, L., Mankin, A. S. (2003). Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics. J. Biol. Chem. 278: 21972-21979 [Abstract] [Full Text]  
  • Mutnick, A. H, Enne, V., Jones, R. N (2003). Linezolid Resistance Since 2001: SENTRY Antimicrobial Surveillance Program. The Annals of Pharmacotherapy 37: 769-774 [Abstract] [Full Text]  
  • Lomaestro, B. M (2003). Resistance to Linezolid. Are We Surprised? How Hard Should We Look?. The Annals of Pharmacotherapy 37: 909-911 [Full Text]  
  • Sakoulas, G., Gold, H. S., Venkataraman, L., Moellering, R. C. Jr, Ferraro, M. J., Eliopoulos, G. M. (2003). Introduction of erm(C) into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility. J Antimicrob Chemother 51: 1039-1041 [Full Text]  
  • Mc Dermott, P. F., Walker, R. D., White, D. G. (2003). Antimicrobials: Modes of Action and Mechanisms of Resistance. International Journal of Toxicology 22: 135-143 [Abstract]  
  • Moellering, R. C. Jr. (2003). Linezolid: The First Oxazolidinone Antimicrobial. ANN INTERN MED 138: 135-142 [Abstract] [Full Text]  
  • Grohs, P., Kitzis, M.-D., Gutmann, L. (2003). In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 418-420 [Abstract] [Full Text]  
  • Simjee, S., White, D. G., Wagner, D. D., Meng, J., Qaiyumi, S., Zhao, S., McDermott, P. F. (2002). Identification of vat(E) in Enterococcus faecalis Isolates from Retail Poultry and Its Transferability to Enterococcus faecium. Antimicrob. Agents Chemother. 46: 3823-3828 [Abstract] [Full Text]  
  • Woodford, N., Tysall, L., Auckland, C., Stockdale, M. W., Lawson, A. J., Walker, R. A., Livermore, D. M. (2002). Detection of Oxazolidinone-Resistant Enterococcus faecalis and Enterococcus faecium Strains by Real-Time PCR and PCR-Restriction Fragment Length Polymorphism Analysis. J. Clin. Microbiol. 40: 4298-4300 [Abstract] [Full Text]  
  • Auckland, C., Teare, L., Cooke, F., Kaufmann, M. E., Warner, M., Jones, G., Bamford, K., Ayles, H., Johnson, A. P. (2002). Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50: 743-746 [Abstract] [Full Text]  
  • Ge, Y., Difuntorum, S., Touami, S., Critchley, I., Burli, R., Jiang, V., Drazan, K., Moser, H. (2002). In Vitro Antimicrobial Activity of GSQ1530, a New Heteroaromatic Polycyclic Compound. Antimicrob. Agents Chemother. 46: 3168-3174 [Abstract] [Full Text]  
  • Marshall, S. H., Donskey, C. J., Hutton-Thomas, R., Salata, R. A., Rice, L. B. (2002). Gene Dosage and Linezolid Resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46: 3334-3336 [Abstract] [Full Text]  
  • Johnson, A. P., Warner, M., Livermore, D. M. (2002). In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci. J Antimicrob Chemother 50: 89-93 [Abstract] [Full Text]  
  • Herrero, I. A., Issa, N. C., Patel, R. (2002). Nosocomial Spread of Linezolid-Resistant, Vancomycin-Resistant Enterococcus faecium. NEJM 346: 867-869 [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prystowsky, J.
Right arrow Articles by Noskin, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prystowsky, J.
Right arrow Articles by Noskin, G. A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»